BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Omasa T, Kim K, Hiramatsu S, Katakura Y, Kishimoto M, Enosawa S, Ohtake H. Construction and Evaluation of Drug-Metabolizing Cell Line for Bioartificial Liver Support System. Biotechnol Progress 2005;21:161-7. [DOI: 10.1021/bp049757a] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Su Y, Chen Z, Yan L, Lian F, You J, Wang X, Tang N. Optimizing combination of liver-enriched transcription factors and nuclear receptors simultaneously favors ammonia and drug metabolism in liver cells. Experimental Cell Research 2018;362:504-14. [DOI: 10.1016/j.yexcr.2017.12.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Araki N, Tsuruoka S, Wang N, Hasegawa G, Yanagihara H, Ando H, Omasa T, Enosawa S, Nagai H, Fujimura A. Human CYP3A4-introduced HepG2 cells: In vitro screening system of new chemicals for the evaluation of CYP3A4-inhibiting activity. Xenobiotica 2008;38:1355-64. [DOI: 10.1080/00498250802468645] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Wang X, Tang N, Zhang F, Li X, Chen Y. Therapeutic evaluation of a microbioartificial liver with recombinant HepG2 cells for rats with hepatic failure. Expert Opinion on Biological Therapy 2013;13:1507-13. [DOI: 10.1517/14712598.2013.843666] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Fieber LA, Greer JB, Guo F, Crawford DC, Rein KS. GENE EXPRESSION PROFILING OF HUMAN LIVER CARCINOMA (HepG2) CELLS EXPOSED TO THE MARINE TOXIN OKADAIC ACID. Toxicol Environ Chem 2012;24:1805-21. [PMID: 23172983 DOI: 10.1080/02772248.2012.730199] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
5 Zhang S, Liu T, Wang Y. Porous and single-skinned polyethersulfone membranes support the growth of HepG2 cells: A potential biomaterial for bioartificial liver systems. J Biomater Appl 2012;27:359-66. [DOI: 10.1177/0885328211406299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
6 Araki N, Tsuruoka S, Hasegawa G, Yanagihara H, Omasa T, Enosawa S, Yamazoe Y, Fujimura A. Inhibition of CYP3A4 by 6',7'-dihydroxybergamottin in human CYP3A4 over-expressed hepG2 cells. J Pharm Pharmacol 2012;64:1715-21. [PMID: 23146034 DOI: 10.1111/j.2042-7158.2012.01562.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Pan X, Li L. Advances in cell sources of hepatocytes for bioartificial liver. Hepatobiliary & Pancreatic Diseases International 2012;11:594-605. [DOI: 10.1016/s1499-3872(12)60230-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]